Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at $6.1 million for Q3 2022.

• In Q3 2022, Change in Accured Expenses fell 30.11% year-over-year to $6.1 million; the TTM figure through Sep 2022 stood at -$13.2 million (down 14556.04% YoY), while the FY2021 annual figure was $10.1 million, up 120.73% from the prior year.
• Change in Accured Expenses was $6.1 million for Q3 2022 at Arcus Biosciences, up from -$15.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $23.0 million in Q3 2020 to a low of -$19.1 million in Q4 2020.
• Historically, Change in Accured Expenses has averaged $748315.8 across 5 years, with a median of $410000.0 in 2018.
• The sharpest annual moves came in 2019 and 2020: Change in Accured Expenses jumped 4569.23% in 2019, then tumbled 11371.43% in 2020.
• A 5-year view of Change in Accured Expenses shows it stood at $1.8 million in 2018, then slipped by 7.6% to $1.7 million in 2019, then slumped by 1221.22% to -$19.1 million in 2020, then jumped by 52.68% to -$9.0 million in 2021, then soared by 167.48% to $6.1 million in 2022.
• The last three Change in Accured Expenses figures came in at $6.1 million (Q3 2022), -$15.8 million (Q2 2022), and $5.6 million (Q1 2022), per Business Quant data.